DOI QR코드

DOI QR Code

Experiences and efficacy of noninvasive prenatal test using maternal plasma in single center: 1,591 cases

  • Hong, So Yeon (Department of Obstetrics and Gynecology, CHA Ilsan Medical Center, CHA University) ;
  • Shim, So Hyun (Department of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University) ;
  • Park, Hee Jin (Department of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University) ;
  • Shim, Sung Shin (Department of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University) ;
  • Kim, Ji Youn (Department of Obstetrics and Gynecology, CHA Ilsan Medical Center, CHA University) ;
  • Cho, Yeon Kyung (Department of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University) ;
  • Kim, Soo Hyun (Department of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University) ;
  • Cha, Dong Hyun (Department of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University)
  • Received : 2020.04.13
  • Accepted : 2020.05.27
  • Published : 2020.06.30

Abstract

Purpose: The objective of this study was to analyze the results of several noninvasive prenatal tests (NIPTs) from a single center and confirm their efficacy and reliability. In addition, we aimed to confirm the changes in the number of invasive tests performed after introducing NIPT. Materials and Methods: NIPT data from a large single center from March 2014 to November 2018 were analyzed. Karyotyping was confirmed based on chorionic villus sampling, amniocentesis, or postnatal cord/peripheral blood sampling. Data on maternal age, gestational age, fetal fraction, and ultrasonographic results were analyzed. As the secondary outcome, the number of amniocentesis cases before and after the introduction of NIPT was compared. Results: Overall, 1,591 single pregnancy cases that underwent NIPT were enrolled. The mean maternal age was 36.05 (22-45) years. The average gestational age and fetal fraction were 12+1 (9+3 to 27+1) weeks and 10.95% (3.6% to 31.3%), respectively. A total of 1,544 cases (97.0%) were reported to have negative NIPT results and 40 (2.5%) had positive NIPT results. The sensitivity and specificity of the overall abnormalities in NIPT were 96.29% and 99.36%, respectively. The positive predictive value (PPV) and negative predictive value were 72.22% and 99.93% respectively. The mean number of amniocentesis cases were 21.7 per month (21.7±3.9), which significantly decreased from 31.5 per month (31.5±4.8) before conducting NIPT as a screening test. Conclusion: NIPT is currently a useful, powerful, and safe screening test. In particular, trisomy 21 is highly specific due to its high PPV. NIPT can reduce the potential risks of procedure-related miscarriages during invasive testing.

Keywords

References

  1. Nicolaides KH. Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn 2011;31:7-15. https://doi.org/10.1002/pd.2637
  2. Simpson JL. Invasive procedures for prenatal diagnosis: any future left? Best Pract Res Clin Obstet Gynaecol 2012;26:625-38. https://doi.org/10.1016/j.bpobgyn.2012.05.007
  3. Akolekar R, Beta J, Picciarelli G, Ogilvie C, D'Antonio F. Procedurerelated risk of miscarriage following amniocentesis and chorionic villus sampling: a systematic review and meta-analysis. Ultrasound Obstet Gynecol 2015;45:16-26. https://doi.org/10.1002/uog.14636
  4. Benn P, Cuckle H, Pergament E. Non-invasive prenatal testing for aneuploidy: current status and future prospects. Ultrasound Obstet Gynecol 2013;42:15-33.
  5. Ramdaney A, Hoskovec J, Harkenrider J, Soto E, Murphy L. Clinical experience with sex chromosome aneuploidies detected by noninvasive prenatal testing (NIPT): accuracy and patient decision-making. Prenat Diagn 2018;38:841-8. https://doi.org/10.1002/pd.5339
  6. Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997;350:485-7. https://doi.org/10.1016/S0140-6736(97)02174-0
  7. Iwarsson E, Jacobsson B, Dagerhamn J, Davidson T, Bernabe E, Heibert Arnlind M. Analysis of cell-free fetal DNA in maternal blood for detection of trisomy 21, 18 and 13 in a general pregnant population and in a high risk population - a systematic review and metaanalysis. Acta Obstet Gynecol Scand 2017;96:7-18. https://doi.org/10.1111/aogs.13047
  8. Flock A, Tu NC, Ruland A, Holzgreve W, Gembruch U, Geipel A. Noninvasive prenatal testing (NIPT): Europe's first multicenter post-market clinical follow-up study validating the quality in clinical routine. Arch Gynecol Obstet 2017;296:923-8. https://doi.org/10.1007/s00404-017-4517-3
  9. Fosler L, Winters P, Jones KW, Curnow KJ, Sehnert AJ, Bhatt S, et al. Aneuploidy screening by non-invasive prenatal testing in twin pregnancy. Ultrasound Obstet Gynecol 2017;49:470-7. https://doi.org/10.1002/uog.15964
  10. Taneja PA, Prosen TL, de Feo E, Kruglyak KM, Halks-Miller M, Curnow KJ, et al. Fetal aneuploidy screening with cell-free DNA in late gestation. J Matern Fetal Neonatal Med 2017;30:338-42. https://doi.org/10.3109/14767058.2016.1172566
  11. Gil MM, Accurti V, Santacruz B, Plana MN, Nicolaides KH. Analysis of cell-free DNA in maternal blood in screening for aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol 2017;50:302-14.
  12. Noh JJ, Ryu HM, Oh SY, Choi SJ, Roh CR, Kim JH. A two-year experience of non-invasive prenatal testing (NIPT) at an urban tertiary medical center in South Korea. Taiwan J Obstet Gynecol 2019;58:545-51. https://doi.org/10.1016/j.tjog.2019.05.021
  13. ACOG Committee on Obstetric Practice. ACOG Committee opinion no. 475: antenatal corticosteroid therapy for fetal maturation. Obstet Gynecol 2011;117(2 Pt 1):422-4. https://doi.org/10.1097/AOG.0b013e31820eee00
  14. Canick JA, Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE. The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies. Prenat Diagn 2013;33:667-74. https://doi.org/10.1002/pd.4126
  15. Wang E, Batey A, Struble C, Musci T, Song K, Oliphant A. Gestational age and maternal weight effects on fetal cell-free DNA in maternal plasma. Prenat Diagn 2013;33:662-6. https://doi.org/10.1002/pd.4119